AstraZeneca plc (ADR)(NYSE:AZN) the makers of commercial-grade asthma and COPD (or Chronic Obstructive Pulmonary Disease) has co-opted long time licentiate in Japan, Kyowa Hakko Kirin, to commercialize its Benralizumab therapeutic solution.
Under the terms and conditions of the ‘exclusive option’ that Astrazeneca offers Kyowa Hakko Kirin will have ‘$45 million upfront option fee.’ Kyowa Hakko Kirin will continue with its development and commercialization activities in Japan for benralizumab.
When the ‘exclusive option’ is exercised AstraZeneca plc (ADR) (NYSE:AZN) will gain rights to marketing and sales in Japan as well. Thus far, AstraZeneca held exclusive rights outside of Japan and some of the Asian countries. Kyowa Hakko Kirin held exclusive development as well as commercialization rights for the drug in Japan and neighboring Asian territories.
AstraZeneca plc (ADR) (NYSE:AZN) new agreement will change the terms to a large extent. Kyowa Hakko Kirin will remain in charge of research and development of benralizumab in Japan. While Astra Zeneca will conduct sales and marketing in Japan, Kyoa Hakko Kirin will be able to participate in selected commercialization activities along with AZN.
Chief Financial Officer of AstraZeneca plc (ADR) (NYSE:AZN), Marc Dunoyer shared that, the agreement will allow the company to continue to grow the platform in the second largest market for drugs in the world. Besides, the agreement with the Japanese firm will allow AstraZeneca to have a sharper ‘focus’ into its core area of therapy namely respiratory diseases, Dunoyer noted. The opportunity to offer new treatment options for Japan-based patients is the added advantage of the new agreement, he shared. Concurring with the CFO, Kyowa Hakko Kirin Executive Officer and Director of Strategic Product Portfolio Department, Masashi Miyamoto, said that, the new agreement would be another step forward to bring optimized medical benefits to patients in the country. Benralizumab is an antibody which works on interleukin-5 receptor or IL-5R alpha to break down eosinophils, the causative in inflammatory respiratory disease.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.